Alnylam Pharmaceuticals ALNY Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's short-term investments?
- Alnylam Pharmaceuticals (ALNY) reported short-term investments of $1.6B in Q2 2026.
- How has Alnylam Pharmaceuticals's short-term investments changed year-over-year?
- Alnylam Pharmaceuticals's short-term investments decreased by 8.3% year-over-year, from $1.74B to $1.6B.
- What is the long-term trend for Alnylam Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's short-term investments has grown at a -1.3% compound annual growth rate (CAGR), from $1.33B to $1.25B.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.